News
Public · Published
RBC Capital maintains Krystal Biotech at Outperform, lowers price target to $375 from $400
RBC Capital kept its Outperform rating on Krystal Biotech but lowered its price target to $375 from $400, a 6.2% decrease. The new target implies 26.7% upside from the November 2 close of $295.90.
Published:
Updated:
What happened
RBC Capital kept its Outperform rating on Krystal Biotech but lowered its price target to $375 from $400, a 6.2% decrease. The new target implies 26.7% upside from the November 2 close of $295.90.
Confirmed
Global impact / market context
A lower price target means RBC still expects the stock to rise but by less than before. Because an Outperform rating signals expected outperformance, the cut trims the expected gain without changing the positive view, so investors get a smaller projected reward.
Analyst inference
Analyst price targets are estimates, not guarantees, and RBC's implied upside depends on the November 2 closing price. A reduced target can reflect updated assumptions about future sales or costs, which may lead some investors to lower their own expectations.
Analyst inference
What to watch
- Watch whether RBC's stated $375 target and its implied 26.7% upside, measured from the November 2 close of $295.90, hold as the stock trades. Confirmed
- Watch whether RBC later changes its Outperform rating or price target again, since another cut would further reduce the expected gain implied by its view. Proposed
- Watch for news on Krystal Biotech's future sales or spending that could explain the lower target, as such changes may shift how investors value the company's profit prospects. Analyst inference
Evidence
- Original source link unavailable